Controlled release
description
Transcript of Controlled release
Manifestation of Novel Social Challenges of the European Unionin the Teaching Material ofMedical Biotechnology Master’s Programmesat the University of Pécs and at the University of DebrecenIdentification number: TÁMOP-4.1.2-08/1/A-2009-0011
CONTROLLED RELEASE
Dr. Judit PongráczThree dimensional tissue cultures and tissue engineering – Lecture 13
Manifestation of Novel Social Challenges of the European Unionin the Teaching Material ofMedical Biotechnology Master’s Programmesat the University of Pécs and at the University of DebrecenIdentification number: TÁMOP-4.1.2-08/1/A-2009-0011
TÁMOP-4.1.2-08/1/A-2009-0011
Controlled drug delivery from scaffolds• Drug release upon matrix degradation• Drug release upon diffusion• Long-term maintenance of effective local
concentration• Localized effects ensured • Limited systemic effects
TÁMOP-4.1.2-08/1/A-2009-0011
Ideal scaffold• 3-dimensional and well defined microstructure• Interconnected pore network • Mechanical properties similar to those of
natural tissues • Biocompatible and bio-resorbable• Controllable degradation and resorption • Local sequestration and controlled delivery of
specific bioactive factors • Thus enhancing and guideing the regeneration
process
TÁMOP-4.1.2-08/1/A-2009-0011
ECM mimicry as a guide for scaffold design• ECM is the natural medium where cells
proliferate, differentiate and migrate• ECM is a highly organized dynamic
biomolecular environment where motifs governing cell behaviours are continuously generated and sequestered
• Motifs are locally released according to cellular stimuli
• Relase occurs on-demand upon degradation of the adhesion sites binding them to the ECM
TÁMOP-4.1.2-08/1/A-2009-0011
Growth factors and the ECM• Growth factors (GFs) are locally stored by
ECM• Storage in insoluble/latent forms • Specific binding with glycosaminoglycans
(e.g. heparins)• Elicit biological activity once released• ECM binding provides concentration gradient
important in morphogenesis
TÁMOP-4.1.2-08/1/A-2009-0011
Mimic the function of ECM• Future generations of TE scaffolds need to
have extended functionality and bioactivity • Synthetic bio-inspired ECM should broadcast
specific cellular events • The ability of controlled release of multiple
bioactive molecules will allow the control of cellular behaviour and successful regeneration
TÁMOP-4.1.2-08/1/A-2009-0011
Interspersed signals• Hydrogels (either natural or synthetic) have
been succesfully used for controlled release of bioactive protein compounds
• Molecules were simply mixed with the polymer and were entrapped upon gelation
• Natural (collagen, fibrin, hyaluronan) and synthetic (PEG-based, peptide-based) hydrogels have been used
• Release characteristic may modulated with crosslinking agents
• Solid-state scaffolds: fabrication method must be mild (to avoid protein denaturation)
TÁMOP-4.1.2-08/1/A-2009-0011
Immobilized signals• Modification of polymer scaffolds to interact with
signaling molecules: immobilization• Prolonged diffusion out of the scaffold platform• Reversible or irreversible binding to the polymer.• Released upon degradation of a linking tether or the
matrix itself• Determinants of the amount of bound signal and
release profile:– The number of binding sites– Affinity of the signal for sites– Degradation rate of the scaffold
TÁMOP-4.1.2-08/1/A-2009-0011
Signal delivery from cells• Inclusion of nucleic acids (NA) encoding the
desired protein• NA are introduced into target cells, which
then produce the desired proteins• Antisense oligos can be used to return
abnormal gene expression to a certain state• Synthetic polymers containing adhesion sites
(RGD) proved to be more effective in delivering the plasmid
TÁMOP-4.1.2-08/1/A-2009-0011
Protein delivery systems (DS) in TE• DS must prevent the protein from
inactivation or degradation• Fine-tuning of the release rate can be
achieved by modulating the composition, shape, and architecture of the platform
• Continous and pulsatile delivery• Biodegradable and non-degradable platforms
TÁMOP-4.1.2-08/1/A-2009-0011
Non-biodegradable systemsEthylene-vinyl acetate copolymers (EVAc) and
silicones:• Mass transport through polymer chains or pores is
the only rate-limiting step• Possible application in cell encapsulation preventing
them to interact with the immune system
Time
TÁMOP-4.1.2-08/1/A-2009-0011
• PLGA is a very versatile and widely used system• Poly-ortho esters are newly in the centre of interest
(no heating or solvents, injectable polymers)• Polyanhydrides usually undergo surface erosion
which has a favorable kinetics
Biodegradable systems
Time
TÁMOP-4.1.2-08/1/A-2009-0011
Controlled release profiles in biodegradable systems
Surface erosion
Bulk erosion
Correspondingrate
Typical releaseprofile
t t
dc(t)
/dt
Release rate
Amou
nt o
f dru
g re
leas
ed
t t t
dc(t)
/dt Toxic dose
c eff(t
)
Protein or smallmolecule drug
Protein or smallmolecule drug
Amou
nt o
f dru
g re
leas
ed Release rate
Correspondingrate
Typical releaseprofile
TÁMOP-4.1.2-08/1/A-2009-0011
On-off drug delivery systems• Pulsatile mode of protein and peptide release • Rapid and transient release of a certain amount of
drug molecules within a short time-period immediately after a pre-determined off-release interval
• Classified into “programmed” and “triggered” delivery systems (DS):– Programmed-DS: the release is governed by the
inner mechanism of the device – Triggered-DS: release is governed by changes in
the physiologic environment of the device or by external stimuli
• External stimuli involve temperature changes, electric or magnetic fields, ultrasounds or irradiation
TÁMOP-4.1.2-08/1/A-2009-0011
Programmed and triggered delivery systems• Synthetic polymers can be engineered to be applicable
in programmed delivery• Both surface and bulk-eroding systems may be used• Biggest interest in triggered delivery is the glucose-
sensitive insulin delivery• The “intelligent” system consists of immobilized
glucose oxidase in a pH-responsive polymeric hydrogel• In the gel, insulin is enclosed• Upon glucose diffusion into the hydrogel, glucose
oxidase converts it into gluconic acid• Lowering of the pH results in gel swelling and insulin
release
TÁMOP-4.1.2-08/1/A-2009-0011
Inclusion of drug molecules into scaffoldsPoly-methyl-methacrylate (PMMA) beads with antibiotics (mostly aminoglycosides):• Orthopedic and trauma surgery• Treatment of chronic osteomyelitis and/or ulcers• Bones and joints are „blind spots” of systemic
antibiotic therapy because the limited blood supply• PMMA beads release antibiotics gradually• High local antibiotic concentration can be achieved• Limited systemic side effects
TÁMOP-4.1.2-08/1/A-2009-0011
Inclusion of bioactive proteins into scaffoldsVEGF role in tissue vascularization:• Cells in hypoxic tissues secrete VEGF• Endothelial cells express VEGFR• Stimulates endothel proliferation• Directs endothelial cell migration• Tissue vascularization is critical in nutrition
and oxigenization of implanted TE constructs• Controlled VEGF delivery is in the focus of TE
research
TÁMOP-4.1.2-08/1/A-2009-0011
VEGF supports TE tissue vascularizationControlled VEGF delivery from alginate microparticles:• Bivalent cations mediate alginate crosslinking• VEGF encapsulation efficiency and delivery
ratio depends on the cation species (Ca2+ or Zn2+)
• Zn2+-crosslinked particles proved to be more toxic than Zn2+
• Mixture of Ca2+ and Zn2+ beads are the most favorable
TÁMOP-4.1.2-08/1/A-2009-0011
Support of tissue differentiation with bioactive proteinsBMP-2: • Key role in regulating osteoblast
differentiation• Recombinant hBMP-2 is dissolved in
aquaeous solution of polyethylene-oxide (PEO)
• rhBMP-2 solution is then added to scaffold material
• Scaffold materials include silk fibroin, PCLA, PEG, PLGA, collagen, etc.
TÁMOP-4.1.2-08/1/A-2009-0011
Experimental results with controlled drug delivery scaffolds – VEGF• Half-life of VEGF is 50 min, therefore
controlled release is critical• Controlled release is based on electrostatic
attractions between the carrier (acidic gelatine, IEP=5.0) and VEGF (IEP=8.6)
• Extent of gelatin cross-linking also influences release
• Up to 90% of total VEGF vas released within 30 days from sc. implants, 80% within the first 5 days.
TÁMOP-4.1.2-08/1/A-2009-0011
Clinical results with controlled drug delivery scaffolds – BMP-2• Use of BMP-2 filled collagen sponges in spinal
degenerative diseases to enhance post-operative bone fusion.
• BMP-2 treated patients regain the ability to self-care and mobility faster, their pain scores are significantly lower.
• Their mood and emotional control is also significantly better than that of control patients.
BIOSENSORS
Dr. Judit PongráczThree dimensional tissue cultures and tissue engineering – Lecture 14
Manifestation of Novel Social Challenges of the European Unionin the Teaching Material ofMedical Biotechnology Master’s Programmesat the University of Pécs and at the University of DebrecenIdentification number: TÁMOP-4.1.2-08/1/A-2009-0011
TÁMOP-4.1.2-08/1/A-2009-0011
Definition Biosensor is a device that transforms or detects a biological signal and transforms into a more easily detectable one.
TÁMOP-4.1.2-08/1/A-2009-0011
Concept of an implantable glucose sensor
Detector(potentially amobile phone)
Glucose sensorImplantable potentiostat
Type I
Signal
Type II
Insulin releaseGlucose sensor
Insulin container
Signal Signal
TÁMOP-4.1.2-08/1/A-2009-0011
Dexamethasone-loaded PLGA Microspheres
10m
TÁMOP-4.1.2-08/1/A-2009-0011
Model of biosensor-tissue interactions
Interphase
Microspherefor drug (TRM)
release
Tissue
Angiogenesis
Hydrogels + PEO
Endothelcell
Sensor
Biosensor
WBC
Angiogenic factor or other tissue response modifiers Fibrin CollagenSoluble proteins
RBC
TÁMOP-4.1.2-08/1/A-2009-0011
The “intelligent” system• Consists of immobilized glucose oxidase in a
pH-responsive polymeric hydrogel, enclosing a saturated insulin solution.
• As glucose diffuses into the hydrogel, glucose oxidase catalyzes its conversion to gluconic acid, thereby lowering the pH in the microenvironment of the membrane.
• Low pH causes swelling and insulin release.
TÁMOP-4.1.2-08/1/A-2009-0011
Development of reliable glucose biosensors require1. Novel electrodes are required to decrease
invasiveness of the implantable glucose biosensor2. Bioactive coatings are necessary to enhance the in
vivo life of the implantable glucose sensor3. Biosensor coating using electrospinning nanofibres
need to be developed4. Tissue responses are needed to be studied further
to optimize tissue responses to biosensor signals5. Angiogenesis around the glucose sensor need to be
increased to enhance detection potential of glucose levels and
6. Finally, novel biostable 3D porous collagen scaffolds need to be developed for tissue compatible biosensors